US 12,441,813 B2
Antibodies for botulinum neurotoxins
James D. Marks, Kensington, CA (US); Maria Consuelo Garcia Rodriguez, San Francisco, CA (US); and Shude Yan, San Bruno, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on Feb. 3, 2022, as Appl. No. 17/592,012.
Application 17/592,012 is a continuation of application No. 17/541,837, filed on Dec. 3, 2021.
Application 17/541,837 is a continuation of application No. 16/813,161, filed on Mar. 9, 2020, granted, now 11,225,525, issued on Jan. 18, 2022.
Application 16/813,161 is a continuation of application No. 15/870,635, filed on Jan. 12, 2018, granted, now 10,618,972, issued on Apr. 14, 2020.
Application 15/870,635 is a continuation of application No. 14/966,959, filed on Dec. 11, 2015, granted, now 9,902,781, issued on Feb. 27, 2018.
Application 14/966,959 is a continuation of application No. 13/813,623, granted, now 9,243,057, issued on Jan. 26, 2016, previously published as PCT/US2011/050050, filed on Aug. 31, 2011.
Claims priority of provisional application 61/430,084, filed on Jan. 5, 2011.
Claims priority of provisional application 61/378,862, filed on Aug. 31, 2010.
Prior Publication US 2022/0251240 A1, Aug. 11, 2022
Int. Cl. C07K 16/40 (2006.01); A61K 39/00 (2006.01); C07K 16/12 (2006.01); G01N 33/569 (2006.01); G01N 33/573 (2006.01)
CPC C07K 16/40 (2013.01) [C07K 16/1282 (2013.01); G01N 33/56911 (2013.01); G01N 33/573 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/20 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); G01N 2333/33 (2013.01); G01N 2333/952 (2013.01)] 19 Claims
OG exemplary drawing
 
1. An isolated antibody, or antigen-binding fragment thereof, that specifically binds a Botulinum neurotoxin (BoNT), wherein the antibody or antigen-binding fragment comprises:
a VH CDR1 comprising the amino acid sequence of NSPYFWN (SEQ ID NO:515),
a VH CDR2 comprising the amino acid sequence of YIYWSGSTNYNPSLKS (SEQ ID NO: 516),
a VH CDR3 comprising the amino acid sequence of DQGGGTVVKENWFDP (SEQ ID NO: 423),
a VL CDR1 comprising the amino acid sequence of QASQDIGKHLN (SEQ ID NO:517),
a VL CDR2 comprising the amino acid sequence of GASNLKT (SEQ ID NO:518), and
a VL CDR3 comprising the amino acid sequence of QQSYSTPPT (SEQ ID NO:519).